AlloVir ALVR

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.02 (+0.21%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of AlloVir (ALVR)
    AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $9.87

    • Market Cap

      $49.76 Million

    • Price-Earnings Ratio

      -4.23

    • Total Outstanding Shares

      5.04 Million Shares

    • Total Employees

      112

    • Dividend

      No dividend

    • IPO Date

      July 30, 2020

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      1100 winter street, Waltham, MA, 02451

    • Homepage

      https://www.allovir.com

    Historical Stock Splits

    If you bought 23 shares of ALVR before January 16, 2025, you'd have 1 share today.
    Execution DateSplit Amount
    January 16, 20251-for-23 (Reverse Split)

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow$11.56 Million
    Net Cash Flow From Operating Activities$-8.44 Million
    Net Cash Flow From Operating Activities, Continuing$-8.44 Million
    Net Cash Flow From Financing Activities$0
    Net Cash Flow From Financing Activities, Continuing$0
    Net Cash Flow, Continuing$11.56 Million

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Operating Income/Loss$-5.72 Million
    Diluted Average Shares$115.40 Million
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Net Income/Loss Attributable To Parent$-4.13 Million
    Preferred Stock Dividends And Other Adjustments$0
    Net Income/Loss$-4.13 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Other Comprehensive Income/Loss$5,000
    Comprehensive Income/Loss Attributable To Parent$-4.12 Million
    Comprehensive Income/Loss$-4.12 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Accounts Payable$51,000
    Equity Attributable To Parent$121.12 Million
    Equity Attributable To Noncontrolling Interest$0
    Liabilities$1.41 Million
    Equity$121.12 Million
    Assets$122.53 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ALVR from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.